These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25469286)

  • 1. Clinical implications of Fas/Fas ligand expression in patients with esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy.
    Saigusa S; Tanaka K; Ohi M; Toiyama Y; Yasuda H; Kitajima T; Okugawa Y; Inoue Y; Mohri Y; Kusunoki M
    Mol Clin Oncol; 2015 Jan; 3(1):151-156. PubMed ID: 25469286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of Fas, Fas ligand, Fas-associated death domain protein, caspase 8 and mutant P53 protein in esophageal squamous cell carcinoma].
    Xue LY; Ren LQ; Luo W; Guan XJ; Zou SM; Zheng S; Bi R; Xie YQ; He ZG; Lü N
    Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(3):150-4. PubMed ID: 17425843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
    Shibakita M; Tachibana M; Dhar DK; Kotoh T; Kinugasa S; Kubota H; Masunaga R; Nagasue N
    Clin Cancer Res; 1999 Sep; 5(9):2464-9. PubMed ID: 10499620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological significance of Fas and Fas ligand expressions in esophageal cancer.
    Wu GZ; Pan CX; Jiang D; Zhang Q; Li Y; Zheng SY
    Am J Cancer Res; 2015; 5(9):2865-71. PubMed ID: 26609492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma.
    Sun T; Miao X; Zhang X; Tan W; Xiong P; Lin D
    J Natl Cancer Inst; 2004 Jul; 96(13):1030-6. PubMed ID: 15240787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy.
    Saigusa S; Mohri Y; Ohi M; Toiyama Y; Ishino Y; Okugawa Y; Tanaka K; Inoue Y; Kusunoki M
    Oncol Rep; 2011 Nov; 26(5):1069-74. PubMed ID: 21811761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy.
    Zhang J; Jiao Q; Kong L; Yu J; Fang A; Li M; Yu J
    Thorac Cancer; 2018 Jun; 9(6):726-735. PubMed ID: 29675925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
    J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.
    Liu SL; Yang H; Zhang P; Zhang L; Zhao L; Luo LL; Fu JH; Liu MZ; Xi M
    Radiother Oncol; 2015 Aug; 116(2):262-8. PubMed ID: 26243678
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Costa EFD; Lima TRP; Lopes-Aguiar L; Nogueira GAS; Visacri MB; Quintanilha JCF; Pincinato EC; Calonga L; Mariano FV; Altemani AMAM; Altemani JMC; Moriel P; Chone CT; Ramos CD; Lima CSP
    Tumour Biol; 2020 Jul; 42(7):1010428320938494. PubMed ID: 32628088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy.
    Huang WT; Lu HI; Wang YM; Chen YH; Lo CM; Lin WC; Lan YC; Tseng LH; Li SH
    J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31684197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy.
    Zhou S; Zhao L; Liang Z; Liu S; Li Y; Liu S; Yang H; Liu M; Xi M
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30717285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
    Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
    Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone.
    Chen Y; Lu Y; Wang Y; Yang H; Xia Y; Chen M; Song H; Li T; Li D; Wang J; Li S; Wang J
    Dis Esophagus; 2014; 27(2):134-40. PubMed ID: 23088212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy.
    Li Q; Zhou S; Liu S; Liu S; Yang H; Zhao L; Liu M; Hu Y; Xi M
    Ann Surg Oncol; 2019 Sep; 26(9):2882-2889. PubMed ID: 31037433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
    Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
    Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer.
    Gratas C; Tohma Y; Barnas C; Taniere P; Hainaut P; Ohgaki H
    Cancer Res; 1998 May; 58(10):2057-62. PubMed ID: 9605741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.